Immuron Announces Sales (Unaudited) Of Travelan A$1.5M, Up 13% Prior Quarter, An OTC Immune Supplement Targeting Pathogenic Bacteria And Toxins Produced In The Gastrointestinal Tract
Portfolio Pulse from Benzinga Newsdesk
Immuron reported unaudited sales of its OTC immune supplement, Travelan, totaling AUD$1.5 million for the September 2024 quarter, marking a 13% increase from the previous quarter. Sales in North America saw a significant rise of 48%.
October 15, 2024 | 10:09 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Immuron's sales of Travelan increased by 13% in the September 2024 quarter, with North American sales up by 48%. This growth indicates strong market performance and potential for further expansion.
The reported increase in sales, especially the significant growth in North America, suggests a positive market reception and potential for further revenue growth. This is likely to positively impact Immuron's stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100